<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240626081808
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240626081808" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 26 Jun 2024 12:18:09 +0000</lastbuilddate>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Pulsed-field ablation: a revolution in atrial fibrillation therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38918558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 25. doi: 10.1038/s41569-024-01053-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38918558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38918558</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01053-7>10.1038/s41569-024-01053-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38918558</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Leonid Maizels</dc:creator>
<dc:creator>Jonathan M Kalman</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Pulsed-field ablation: a revolution in atrial fibrillation therapy</dc:title>
<dc:identifier>pmid:38918558</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01053-7</dc:identifier>
</item>
<item>
<title>Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP into A Paradigm of Integrated Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 13:S0735-1097(24)07557-0. doi: 10.1016/j.jacc.2024.06.006. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917937</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.006>10.1016/j.jacc.2024.06.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917937</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Anuradha Lala</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP into A Paradigm of Integrated Care</dc:title>
<dc:identifier>pmid:38917937</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.006</dc:identifier>
</item>
<item>
<title>The primitive endoderm supports lineage plasticity to enable regulative development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917790/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Mammalian blastocyst formation involves the specification of the trophectoderm followed by the differentiation of the inner cell mass into embryonic epiblast and extra-embryonic primitive endoderm (PrE). During this time, the embryo maintains a window of plasticity and can redirect its cellular fate when challenged experimentally. In this context, we found that the PrE alone was sufficient to regenerate a complete blastocyst and continue post-implantation development. We identify an in vitro...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20:S0092-8674(24)00595-6. doi: 10.1016/j.cell.2024.05.051. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mammalian blastocyst formation involves the specification of the trophectoderm followed by the differentiation of the inner cell mass into embryonic epiblast and extra-embryonic primitive endoderm (PrE). During this time, the embryo maintains a window of plasticity and can redirect its cellular fate when challenged experimentally. In this context, we found that the PrE alone was sufficient to regenerate a complete blastocyst and continue post-implantation development. We identify an in vitro population similar to the early PrE in vivo that exhibits the same embryonic and extra-embryonic potency and can form complete stem cell-based embryo models, termed blastoids. Commitment in the PrE is suppressed by JAK/STAT signaling, collaborating with OCT4 and the sustained expression of a subset of pluripotency-related transcription factors that safeguard an enhancer landscape permissive for multi-lineage differentiation. Our observations support the notion that transcription factor persistence underlies plasticity in regulative development and highlight the importance of the PrE in perturbed development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917790/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917790</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.051>10.1016/j.cell.2024.05.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917790</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Madeleine Linneberg-Agerholm</dc:creator>
<dc:creator>Annika Charlotte Sell</dc:creator>
<dc:creator>Alba Redó-Riveiro</dc:creator>
<dc:creator>Marta Perera</dc:creator>
<dc:creator>Martin Proks</dc:creator>
<dc:creator>Teresa E Knudsen</dc:creator>
<dc:creator>Antonio Barral</dc:creator>
<dc:creator>Miguel Manzanares</dc:creator>
<dc:creator>Joshua M Brickman</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The primitive endoderm supports lineage plasticity to enable regulative development</dc:title>
<dc:identifier>pmid:38917790</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.051</dc:identifier>
</item>
<item>
<title>Open-ST: High-resolution spatial transcriptomics in 3D</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Spatial transcriptomics (ST) methods unlock molecular mechanisms underlying tissue development, homeostasis, or disease. However, there is a need for easy-to-use, high-resolution, cost-efficient, and 3D-scalable methods. Here, we report Open-ST, a sequencing-based, open-source experimental and computational resource to address these challenges and to study the molecular organization of tissues in 2D and 3D. In mouse brain, Open-ST captured transcripts at subcellular resolution and reconstructed...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 21:S0092-8674(24)00636-6. doi: 10.1016/j.cell.2024.05.055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Spatial transcriptomics (ST) methods unlock molecular mechanisms underlying tissue development, homeostasis, or disease. However, there is a need for easy-to-use, high-resolution, cost-efficient, and 3D-scalable methods. Here, we report Open-ST, a sequencing-based, open-source experimental and computational resource to address these challenges and to study the molecular organization of tissues in 2D and 3D. In mouse brain, Open-ST captured transcripts at subcellular resolution and reconstructed cell types. In primary head-and-neck tumors and patient-matched healthy/metastatic lymph nodes, Open-ST captured the diversity of immune, stromal, and tumor populations in space, validated by imaging-based ST. Distinct cell states were organized around cell-cell communication hotspots in the tumor but not the metastasis. Strikingly, the 3D reconstruction and multimodal analysis of the metastatic lymph node revealed spatially contiguous structures not visible in 2D and potential biomarkers precisely at the 3D tumor/lymph node boundary. All protocols and software are available at https://rajewsky-lab.github.io/openst.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917789</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.055>10.1016/j.cell.2024.05.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917789</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marie Schott</dc:creator>
<dc:creator>Daniel León-Periñán</dc:creator>
<dc:creator>Elena Splendiani</dc:creator>
<dc:creator>Leon Strenger</dc:creator>
<dc:creator>Jan Robin Licha</dc:creator>
<dc:creator>Tancredi Massimo Pentimalli</dc:creator>
<dc:creator>Simon Schallenberg</dc:creator>
<dc:creator>Jonathan Alles</dc:creator>
<dc:creator>Sarah Samut Tagliaferro</dc:creator>
<dc:creator>Anastasiya Boltengagen</dc:creator>
<dc:creator>Sebastian Ehrig</dc:creator>
<dc:creator>Stefano Abbiati</dc:creator>
<dc:creator>Steffen Dommerich</dc:creator>
<dc:creator>Massimiliano Pagani</dc:creator>
<dc:creator>Elisabetta Ferretti</dc:creator>
<dc:creator>Giuseppe Macino</dc:creator>
<dc:creator>Nikos Karaiskos</dc:creator>
<dc:creator>Nikolaus Rajewsky</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Open-ST: High-resolution spatial transcriptomics in 3D</dc:title>
<dc:identifier>pmid:38917789</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.055</dc:identifier>
</item>
<item>
<title>Pan-cancer proteogenomics expands the landscape of therapeutic targets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data from 1,043 patients across 10 cancer types with additional public datasets to identify potential therapeutic targets. Pan-cancer analysis of 2,863 druggable proteins reveals a wide abundance range and identifies biological factors that affect mRNA-protein correlation. Integration of proteomic data from...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 17:S0092-8674(24)00583-X. doi: 10.1016/j.cell.2024.05.039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data from 1,043 patients across 10 cancer types with additional public datasets to identify potential therapeutic targets. Pan-cancer analysis of 2,863 druggable proteins reveals a wide abundance range and identifies biological factors that affect mRNA-protein correlation. Integration of proteomic data from tumors and genetic screen data from cell lines identifies protein overexpression- or hyperactivation-driven druggable dependencies, enabling accurate predictions of effective drug targets. Proteogenomic identification of synthetic lethality provides a strategy to target tumor suppressor gene loss. Combining proteogenomic analysis and MHC binding prediction prioritizes mutant KRAS peptides as promising public neoantigens. Computational identification of shared tumor-associated antigens followed by experimental confirmation nominates peptides as immunotherapy targets. These analyses, summarized at https://targets.linkedomics.org, form a comprehensive landscape of protein and peptide targets for companion diagnostics, drug repurposing, and therapy development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917788</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.039>10.1016/j.cell.2024.05.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917788</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sara R Savage</dc:creator>
<dc:creator>Xinpei Yi</dc:creator>
<dc:creator>Jonathan T Lei</dc:creator>
<dc:creator>Bo Wen</dc:creator>
<dc:creator>Hongwei Zhao</dc:creator>
<dc:creator>Yuxing Liao</dc:creator>
<dc:creator>Eric J Jaehnig</dc:creator>
<dc:creator>Lauren K Somes</dc:creator>
<dc:creator>Paul W Shafer</dc:creator>
<dc:creator>Tobie D Lee</dc:creator>
<dc:creator>Zile Fu</dc:creator>
<dc:creator>Yongchao Dou</dc:creator>
<dc:creator>Zhiao Shi</dc:creator>
<dc:creator>Daming Gao</dc:creator>
<dc:creator>Valentina Hoyos</dc:creator>
<dc:creator>Qiang Gao</dc:creator>
<dc:creator>Bing Zhang</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Pan-cancer proteogenomics expands the landscape of therapeutic targets</dc:title>
<dc:identifier>pmid:38917788</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.039</dc:identifier>
</item>
<item>
<title>Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Intravenous iron therapy with FCM delivers iron to the myocardium rapidly through NTBI transporters, independently of reticuloendothelial macrophages. This iron remains labile for weeks, reflecting the myocardium's limited iron storage capacity. These findings challenge current notions of how the heart obtains iron from these therapies and highlight the potential for long-term dosing to cause cumulative iron build-up in the heart.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 25:ehae359. doi: 10.1093/eurheartj/ehae359. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Intravenous iron therapies contain iron-carbohydrate complexes, designed to ensure iron becomes bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other tissues obtain and handle this iron remains unknown. This study addresses this question in the context of the heart.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A prospective observational study was conducted in 12 patients receiving ferric carboxymaltose (FCM) for iron deficiency. Myocardial, spleen, and liver magnetic resonance relaxation times and plasma iron markers were collected longitudinally. To examine the handling of iron taken up by the myocardium, intracellular labile iron pool (LIP) was imaged in FCM-treated mice and cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In patients, myocardial relaxation time T1 dropped maximally 3 h post-FCM, remaining low 42 days later, while splenic T1 dropped maximally at 14 days, recovering by 42 days. In plasma, non-transferrin-bound iron (NTBI) peaked at 3 h, while ferritin peaked at 14 days. Changes in liver T1 diverged among patients. In mice, myocardial LIP rose 1 h and remained elevated 42 days after FCM. In cardiomyocytes, FCM exposure raised LIP rapidly. This was prevented by inhibitors of NTBI transporters T-type and L-type calcium channels and divalent metal transporter 1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Intravenous iron therapy with FCM delivers iron to the myocardium rapidly through NTBI transporters, independently of reticuloendothelial macrophages. This iron remains labile for weeks, reflecting the myocardium's limited iron storage capacity. These findings challenge current notions of how the heart obtains iron from these therapies and highlight the potential for long-term dosing to cause cumulative iron build-up in the heart.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917062</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae359>10.1093/eurheartj/ehae359</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917062</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Mayra Vera-Aviles</dc:creator>
<dc:creator>Syeeda Nashitha Kabir</dc:creator>
<dc:creator>Akshay Shah</dc:creator>
<dc:creator>Paolo Polzella</dc:creator>
<dc:creator>Dillon Yee Lim</dc:creator>
<dc:creator>Poppy Buckley</dc:creator>
<dc:creator>Charlotte Ball</dc:creator>
<dc:creator>Dorine Swinkels</dc:creator>
<dc:creator>Hanke Matlung</dc:creator>
<dc:creator>Colin Blans</dc:creator>
<dc:creator>Philip Holdship</dc:creator>
<dc:creator>Jeremy Nugent</dc:creator>
<dc:creator>Edward Anderson</dc:creator>
<dc:creator>Michael Desborough</dc:creator>
<dc:creator>Stefan Piechnik</dc:creator>
<dc:creator>Vanessa Ferreira</dc:creator>
<dc:creator>Samira Lakhal-Littleton</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway</dc:title>
<dc:identifier>pmid:38917062</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae359</dc:identifier>
</item>
<item>
<title>Correction to: Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 25:ehae396. doi: 10.1093/eurheartj/ehae396. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917060</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae396>10.1093/eurheartj/ehae396</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917060</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score</dc:title>
<dc:identifier>pmid:38917060</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae396</dc:identifier>
</item>
<item>
<title>APOLLO: advanced magnetic probes for minimally invasive endovascular interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38917048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 25:ehae155. doi: 10.1093/eurheartj/ehae155. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38917048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38917048</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae155>10.1093/eurheartj/ehae155</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38917048</guid>
<pubDate>Tue, 25 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Michiel Richter</dc:creator>
<dc:creator>Venkatasubramanian Kalpathy Venkiteswaran</dc:creator>
<dc:creator>Jean-Paul de Vries</dc:creator>
<dc:creator>Sarthak Misra</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>APOLLO: advanced magnetic probes for minimally invasive endovascular interventions</dc:title>
<dc:identifier>pmid:38917048</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae155</dc:identifier>
</item>
<item>
<title>Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38913004/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with obesity-related HFpEF, fewer semaglutide-treated than placebo-treated patients had a deterioration, and more had an improvement, in NYHA functional class at 52 weeks. Semaglutide consistently improved HF-related symptoms, physical limitations, and exercise function, and reduced bodyweight and biomarkers of inflammation and congestion in all NYHA functional class categories. Semaglutide-mediated improvements in health status were especially large in patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07126-2. doi: 10.1016/j.jacc.2024.04.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms, physical limitations, and exercise function, and reduced bodyweight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Whether semaglutide improves functional status, as assessed by NYHA functional class, is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to examine the effects of semaglutide on change in NYHA functional class over time. We also investigated the effects of semaglutide on HF-related symptoms, physical limitations, and bodyweight and other trial endpoints across baseline NYHA functional class categories.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a prespecified analysis of pooled data from 2 international, double-blind, randomized trials (STEP-HFpEF and STEP-HFpEF type 2 diabetes [STEP-HFpEF DM], comprising the STEP-HFpEF program), which collectively randomized 1,145 participants with obesity-related HFpEF to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. The outcome of interest for this analysis was the change in NYHA functional class (baseline to 52 weeks). We also investigated the effects of semaglutide on the dual primary, confirmatory secondary, and selected exploratory endpoints according to baseline NYHA functional class.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: More semaglutide-treated than placebo-treated patients had an improvement in NYHA functional class (32.6% vs 21.5%, respectively; OR: 2.20 [95% CI: 1.62-2.99; P &lt; 0.001]) and fewer semaglutide-treated patients experienced deterioration in NYHA functional class (2.09% vs 5.24%, respectively; OR: 0.36 [95% CI: 0.19-0.70; P = 0.003]) at 52 weeks. Semaglutide (vs placebo) improved the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CCS) across NYHA functional class categories; this was especially pronounced in those in NYHA functional classes III/IV (10.5 points [95% CI: 6.6-14.4 points]) vs NYHA functional class II (6.0 points [95% CI: 3.4-8.6 points]) (P interaction = 0.06). By contrast, the degree of reduction in bodyweight was similar with semaglutide vs placebo regardless of baseline NYHA functional class category (NYHA functional class II, -8.4% [95% CI: -9.4% to -7.3%]; NYHA functional classes III/IV, -8.3% [95% CI: -9.9% to -6.8%]; P interaction = 0.96). Semaglutide consistently improved 6-minute walking distance (6MWD), the hierarchical composite endpoint (death, HF events, differences in KCCQ-CSS, and 6MWD changes), and reduced C-reactive protein and N-terminal prohormone of brain natriuretic peptide across NYHA functional class categories (all P interactions = NS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with obesity-related HFpEF, fewer semaglutide-treated than placebo-treated patients had a deterioration, and more had an improvement, in NYHA functional class at 52 weeks. Semaglutide consistently improved HF-related symptoms, physical limitations, and exercise function, and reduced bodyweight and biomarkers of inflammation and congestion in all NYHA functional class categories. Semaglutide-mediated improvements in health status were especially large in patients with NYHA functional classes III/IV. (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure and Obesity; NCT04788511) (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes; NCT04916470).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38913004/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38913004</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.038>10.1016/j.jacc.2024.04.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38913004</guid>
<pubDate>Mon, 24 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Melanie J Davies</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Shachi Patel</dc:creator>
<dc:creator>Khaja M Chinnakondepalli</dc:creator>
<dc:creator>Signe Harring</dc:creator>
<dc:creator>Steen Z Abildstrøm</dc:creator>
<dc:creator>Karoline Liisberg</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>STEP-HFpEF Trial Committees and Investigators</dc:creator>
<dc:date>2024-06-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program</dc:title>
<dc:identifier>pmid:38913004</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.038</dc:identifier>
</item>
<item>
<title>Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38913003/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide 2.4 mg reduced body weight to a greater extent in women, and produced similar improvements in HF-related symptoms, physical limitations, and exercise function, regardless of sex. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511; and Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445-X. doi: 10.1016/j.jacc.2024.06.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: More women than men have heart failure with preserved ejection fraction (HFpEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess baseline characteristics and treatment effect of semaglutide by sex across the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a prespecified secondary analysis of pooled data from STEP-HFpEF and STEP-HFpEF DM (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes), patients with heart failure (HF), left ventricular ejection fraction ≥45%, body mass index ≥30 kg/m<sup>2</sup>, and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) &lt;90 points were randomized 1:1 to once-weekly semaglutide 2.4 mg or matched placebo for 52 weeks. Dual primary endpoints (KCCQ-CSS change and percentage change in body weight) and confirmatory secondary endpoints (6-minute walking distance [6MWD] change; hierarchical composite endpoint comprising all-cause death, HF events, changes in KCCQ-CSS, and 6MWD; and C-reactive protein) were compared between sexes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1,145 patients, 570 (49.7%) were women. Women had higher body mass index, left ventricular ejection fraction, C-reactive protein, and worse HF symptoms, and were less likely to have atrial fibrillation or coronary artery disease vs men. Semaglutide improved KCCQ-CSS regardless of sex (mean difference in women +7.6 points [95% CI: 4.5-10.7 points]; men +7.5 points [95% CI: 4.3-10.6 points]; P interaction = 0.94) but reduced body weight more in women (mean difference in women -9.6% [95% CI: -10.9% to -8.4%]; men -7.2% [95% CI: -8.4% to -6.0%]; P interaction = 0.006). Semaglutide improved 6MWD (P interaction = 0.21) and the hierarchical composite endpoint (P interaction = 0.66) in both sexes. Fewer serious adverse events were reported with semaglutide vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide 2.4 mg reduced body weight to a greater extent in women, and produced similar improvements in HF-related symptoms, physical limitations, and exercise function, regardless of sex. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511; and Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP HFpEF DM]; NCT04916470).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38913003/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38913003</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.001>10.1016/j.jacc.2024.06.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38913003</guid>
<pubDate>Mon, 24 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Melanie Davies</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Eric Barros</dc:creator>
<dc:creator>Cecilia Rönnbäck</dc:creator>
<dc:creator>Lene Sommer Vestergaard</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Shachi Patel</dc:creator>
<dc:creator>Khaja M Chinnakondepalli</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>STEP-HFpEF Trial Committees and Investigators</dc:creator>
<dc:date>2024-06-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials</dc:title>
<dc:identifier>pmid:38913003</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.001</dc:identifier>
</item>
<item>
<title>Heart Failure With Preserved Ejection Fraction: Prioritizing Patients' Symptoms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38913002/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 11:S0735-1097(24)07300-5. doi: 10.1016/j.jacc.2024.05.017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38913002/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38913002</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.017>10.1016/j.jacc.2024.05.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38913002</guid>
<pubDate>Mon, 24 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Antonio Cannata</dc:creator>
<dc:creator>Daniel I Bromage</dc:creator>
<dc:creator>Susan E Piper</dc:creator>
<dc:creator>Theresa A McDonagh</dc:creator>
<dc:date>2024-06-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Heart Failure With Preserved Ejection Fraction: Prioritizing Patients' Symptoms</dc:title>
<dc:identifier>pmid:38913002</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.017</dc:identifier>
</item>
<item>
<title>Impaired Intracellular Calcium Buffering Contributes to the Arrhythmogenic Substrate in Atrial Myocytes From Patients With Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38910563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings suggest that loss of myofilament proteins, particularly reduced cTnC protein levels, causes diminished cytosolic Ca^(2+) buffering in persAF, thereby potentiating the occurrence of spontaneous Ca^(2+) release events and AF susceptibility. Strategies targeting intracellular buffering may represent a promising therapeutic lead in AF management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 24. doi: 10.1161/CIRCULATIONAHA.123.066577. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Alterations in the buffering of intracellular Ca<sup>2+</sup>, for which myofilament proteins play a key role, have been shown to promote cardiac arrhythmia. It is interesting that although studies report atrial myofibrillar degradation in patients with persistent atrial fibrillation (persAF), the intracellular Ca<sup>2+</sup> buffering profile in persAF remains obscure. Therefore, we aim to investigate the intracellular buffering of calcium and its potential arrhythmogenic role in persAF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Simultaneous transmembrane fluxes (patch-clamp) and intracellular Ca<sup>2+</sup> signaling (fluo-3-acetoxymethyl ester) were recorded in myocytes from right atrial biopsies of sinus rhythm (control) and patients with persAF, alongside human atrial subtype induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs). Protein levels were quantified by immunoblotting of human atrial tissue and induced pluripotent stem cell-derived cardiac myocytes. Mouse whole heart and atrial electrophysiology was measured on a Langendorff system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cytosolic Ca<sup>2+</sup> buffering was decreased in atrial myocytes of patients with persAF because of a depleted amount of Ca<sup>2+</sup> buffers. In agreement, protein levels of selected Ca<sup>2+</sup> binding myofilament proteins, including cTnC (cardiac troponin C), a major cytosolic Ca<sup>2+</sup> buffer, were significantly lower in patients with persAF. Small interfering RNA (siRNA)-mediated knockdown of cTnC in induced pluripotent stem cell-derived cardiac myocytes (si-cTnC) phenocopied the reduced cytosolic Ca<sup>2+</sup> buffering observed in persAF. Si-cTnC induced pluripotent stem cell-derived cardiac myocytes exhibited a higher predisposition to spontaneous Ca<sup>2+</sup> release events and developed action potential alternans at low stimulation frequencies. Last, indirect reduction of cytosolic Ca<sup>2+</sup> buffering using blebbistatin in an ex vivo mouse whole heart model increased vulnerability to tachypacing-induced atrial arrhythmia, validating the direct mechanistic link between impaired cytosolic Ca<sup>2+</sup> buffering and atrial arrhythmogenesis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings suggest that loss of myofilament proteins, particularly reduced cTnC protein levels, causes diminished cytosolic Ca<sup>2+</sup> buffering in persAF, thereby potentiating the occurrence of spontaneous Ca<sup>2+</sup> release events and AF susceptibility. Strategies targeting intracellular buffering may represent a promising therapeutic lead in AF management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38910563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38910563</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066577>10.1161/CIRCULATIONAHA.123.066577</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38910563</guid>
<pubDate>Mon, 24 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Funsho E Fakuade</dc:creator>
<dc:creator>Dominik Hubricht</dc:creator>
<dc:creator>Vanessa Möller</dc:creator>
<dc:creator>Izzatullo Sobitov</dc:creator>
<dc:creator>Aiste Liutkute</dc:creator>
<dc:creator>Yannic Döring</dc:creator>
<dc:creator>Fitzwilliam Seibertz</dc:creator>
<dc:creator>Marcus Gerloff</dc:creator>
<dc:creator>Julius Ryan D Pronto</dc:creator>
<dc:creator>Fereshteh Haghighi</dc:creator>
<dc:creator>Sören Brandenburg</dc:creator>
<dc:creator>Khaled Alhussini</dc:creator>
<dc:creator>Nadezda Ignatyeva</dc:creator>
<dc:creator>Yara Bonhoff</dc:creator>
<dc:creator>Stefanie Kestel</dc:creator>
<dc:creator>Aschraf El-Essawi</dc:creator>
<dc:creator>Ahmad Fawad Jebran</dc:creator>
<dc:creator>Marius Großmann</dc:creator>
<dc:creator>Bernhard C Danner</dc:creator>
<dc:creator>Hassina Baraki</dc:creator>
<dc:creator>Constanze Schmidt</dc:creator>
<dc:creator>Samuel Sossalla</dc:creator>
<dc:creator>Ingo Kutschka</dc:creator>
<dc:creator>Constanze Bening</dc:creator>
<dc:creator>Christoph Maack</dc:creator>
<dc:creator>Wolfgang A Linke</dc:creator>
<dc:creator>Jordi Heijman</dc:creator>
<dc:creator>Stephan E Lehnart</dc:creator>
<dc:creator>George Kensah</dc:creator>
<dc:creator>Antje Ebert</dc:creator>
<dc:creator>Fleur E Mason</dc:creator>
<dc:creator>Niels Voigt</dc:creator>
<dc:date>2024-06-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impaired Intracellular Calcium Buffering Contributes to the Arrhythmogenic Substrate in Atrial Myocytes From Patients With Atrial Fibrillation</dc:title>
<dc:identifier>pmid:38910563</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066577</dc:identifier>
</item>
<item>
<title>Adverse Cardiovascular Outcomes in Patients with Obstructive Sleep Apnea and Obesity: Metabolic Surgery versus Usual Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38909919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with moderate-to-severe OSA and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MACE and death.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 13:S0735-1097(24)07559-4. doi: 10.1016/j.jacc.2024.06.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: No therapy has been shown to reduce the risk of major adverse cardiovascular events (MACE) and death in patients with obstructive sleep apnea (OSA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To investigate the long-term relationship between metabolic surgery and incident MACE in patients with OSA and obesity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adult patients with BMI 35-70 kg/m<sup>2</sup> and moderate-to-severe OSA at a US health system (2004-2018) were identified. Baseline characteristics of patients who underwent metabolic surgery were balanced with a nonsurgical control group using overlap weighting methods. Multivariable Cox regression analysis estimated time-to-incident MACE. Follow-up ended in September 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 13,657 patients (7496 [54.9%] men; mean age, 52.0 years [SD 12.4]; median BMI, 41.0 [IQR, 37.6-46.2]), including 970 patients in the metabolic surgery group and 12,687 patients in the nonsurgical group, with a median follow-up of 5.3 years (IQR, 3.1-8.4 years) were analyzed. The mean between-group difference in body weight at 10 years was 26.6 kg (95% CI, 25.6-27.6) or 19.3% (95% CI, 18.6%-19.9%). The 10-year cumulative incidence of MACE was 27.0% (95% CI, 21.6%-32.0%) in the metabolic surgery group and 35.6% (95% CI, 33.8%-37.4%) in the nonsurgical group (adjusted HR, 0.58 [95% CI, 0.48-0.71], P &lt; .001). The 10-year cumulative incidence of all-cause mortality was 9.1% (95% CI, 5.7%-12.4%) in the metabolic surgery group and 12.5% (95% CI, 11.2%-13.8%) in the nonsurgical group (adjusted HR, 0.63 [95% CI, 0.45-0.89], P = .009).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with moderate-to-severe OSA and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MACE and death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38909919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38909919</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.008>10.1016/j.jacc.2024.06.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38909919</guid>
<pubDate>Sun, 23 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ali Aminian</dc:creator>
<dc:creator>Lu Wang</dc:creator>
<dc:creator>Abdullah Al Jabri</dc:creator>
<dc:creator>Rickesha Wilson</dc:creator>
<dc:creator>James Bena</dc:creator>
<dc:creator>Alex Milinovich</dc:creator>
<dc:creator>Jian Jin</dc:creator>
<dc:creator>Catherine Heinzinger</dc:creator>
<dc:creator>Cinthya Pena-Orbea</dc:creator>
<dc:creator>Nancy Foldvary-Schaefer</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:date>2024-06-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Adverse Cardiovascular Outcomes in Patients with Obstructive Sleep Apnea and Obesity: Metabolic Surgery versus Usual Care</dc:title>
<dc:identifier>pmid:38909919</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.008</dc:identifier>
</item>
<item>
<title>Systematic mapping of organism-scale gene-regulatory networks in aging using population asynchrony</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38908368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>In aging, physiologic networks decline in function at rates that differ between individuals, producing a wide distribution of lifespan. Though 70% of human lifespan variance remains unexplained by heritable factors, little is known about the intrinsic sources of physiologic heterogeneity in aging. To understand how complex physiologic networks generate lifespan variation, new methods are needed. Here, we present Asynch-seq, an approach that uses gene-expression heterogeneity within isogenic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 21:S0092-8674(24)00594-4. doi: 10.1016/j.cell.2024.05.050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In aging, physiologic networks decline in function at rates that differ between individuals, producing a wide distribution of lifespan. Though 70% of human lifespan variance remains unexplained by heritable factors, little is known about the intrinsic sources of physiologic heterogeneity in aging. To understand how complex physiologic networks generate lifespan variation, new methods are needed. Here, we present Asynch-seq, an approach that uses gene-expression heterogeneity within isogenic populations to study the processes generating lifespan variation. By collecting thousands of single-individual transcriptomes, we capture the Caenorhabditis elegans "pan-transcriptome"-a highly resolved atlas of non-genetic variation. We use our atlas to guide a large-scale perturbation screen that identifies the decoupling of total mRNA content between germline and soma as the largest source of physiologic heterogeneity in aging, driven by pleiotropic genes whose knockdown dramatically reduces lifespan variance. Our work demonstrates how systematic mapping of physiologic heterogeneity can be applied to reduce inter-individual disparities in aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38908368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38908368</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.050>10.1016/j.cell.2024.05.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38908368</guid>
<pubDate>Sat, 22 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthias Eder</dc:creator>
<dc:creator>Olivier M F Martin</dc:creator>
<dc:creator>Natasha Oswal</dc:creator>
<dc:creator>Lucia Sedlackova</dc:creator>
<dc:creator>Cátia Moutinho</dc:creator>
<dc:creator>Andrea Del Carmen-Fabregat</dc:creator>
<dc:creator>Simon Menendez Bravo</dc:creator>
<dc:creator>Arnau Sebé-Pedrós</dc:creator>
<dc:creator>Holger Heyn</dc:creator>
<dc:creator>Nicholas Stroustrup</dc:creator>
<dc:date>2024-06-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Systematic mapping of organism-scale gene-regulatory networks in aging using population asynchrony</dc:title>
<dc:identifier>pmid:38908368</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.050</dc:identifier>
</item>
<item>
<title>TERT activation targets DNA methylation and multiple aging hallmarks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38908367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Insufficient telomerase activity, stemming from low telomerase reverse transcriptase (TERT) gene transcription, contributes to telomere dysfunction and aging pathologies. Besides its traditional function in telomere synthesis, TERT acts as a transcriptional co-regulator of genes pivotal in aging and age-associated diseases. Here, we report the identification of a TERT activator compound (TAC) that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. In primary human cells and naturally...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 13:S0092-8674(24)00592-0. doi: 10.1016/j.cell.2024.05.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Insufficient telomerase activity, stemming from low telomerase reverse transcriptase (TERT) gene transcription, contributes to telomere dysfunction and aging pathologies. Besides its traditional function in telomere synthesis, TERT acts as a transcriptional co-regulator of genes pivotal in aging and age-associated diseases. Here, we report the identification of a TERT activator compound (TAC) that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. In primary human cells and naturally aged mice, TAC-induced elevation of TERT levels promotes telomere synthesis, blunts tissue aging hallmarks with reduced cellular senescence and inflammatory cytokines, and silences p16<sup>INK4a</sup> expression via upregulation of DNMT3B-mediated promoter hypermethylation. In the brain, TAC alleviates neuroinflammation, increases neurotrophic factors, stimulates adult neurogenesis, and preserves cognitive function without evident toxicity, including cancer risk. Together, these findings underscore TERT's critical role in aging processes and provide preclinical proof of concept for physiological TERT activation as a strategy to mitigate multiple aging hallmarks and associated pathologies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38908367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38908367</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.048>10.1016/j.cell.2024.05.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38908367</guid>
<pubDate>Sat, 22 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Hong Seok Shim</dc:creator>
<dc:creator>Jonathan Iaconelli</dc:creator>
<dc:creator>Xiaoying Shang</dc:creator>
<dc:creator>Jiexi Li</dc:creator>
<dc:creator>Zheng D Lan</dc:creator>
<dc:creator>Shan Jiang</dc:creator>
<dc:creator>Kayla Nutsch</dc:creator>
<dc:creator>Brittney B Beyer</dc:creator>
<dc:creator>Luke L Lairson</dc:creator>
<dc:creator>Adam T Boutin</dc:creator>
<dc:creator>Michael J Bollong</dc:creator>
<dc:creator>Peter G Schultz</dc:creator>
<dc:creator>Ronald A DePinho</dc:creator>
<dc:date>2024-06-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TERT activation targets DNA methylation and multiple aging hallmarks</dc:title>
<dc:identifier>pmid:38908367</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.048</dc:identifier>
</item>
<item>
<title>The evolution of developmental biology through conceptual and technological revolutions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38906136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Developmental biology-the study of the processes by which cells, tissues, and organisms develop and change over time-has entered a new golden age. After the molecular genetics revolution in the 80s and 90s and the diversification of the field in the early 21st century, we have entered a phase when powerful technologies provide new approaches and open unexplored avenues. Progress in the field has been accelerated by advances in genomics, imaging, engineering, and computational biology and by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 13:S0092-8674(24)00632-9. doi: 10.1016/j.cell.2024.05.053. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Developmental biology-the study of the processes by which cells, tissues, and organisms develop and change over time-has entered a new golden age. After the molecular genetics revolution in the 80s and 90s and the diversification of the field in the early 21st century, we have entered a phase when powerful technologies provide new approaches and open unexplored avenues. Progress in the field has been accelerated by advances in genomics, imaging, engineering, and computational biology and by emerging model systems ranging from tardigrades to organoids. We summarize how revolutionary technologies have led to remarkable progress in understanding animal development. We describe how classic questions in gene regulation, pattern formation, morphogenesis, organogenesis, and stem cell biology are being revisited. We discuss the connections of development with evolution, self-organization, metabolism, time, and ecology. We speculate how developmental biology might evolve in an era of synthetic biology, artificial intelligence, and human engineering.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38906136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38906136</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.053>10.1016/j.cell.2024.05.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38906136</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Prisca Liberali</dc:creator>
<dc:creator>Alexander F Schier</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The evolution of developmental biology through conceptual and technological revolutions</dc:title>
<dc:identifier>pmid:38906136</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.053</dc:identifier>
</item>
<item>
<title>Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38906102/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>The gut microbiota influences the clinical responses of cancer patients to immunecheckpoint inhibitors (ICIs). However, there is no consensus definition of detrimental dysbiosis. Based on metagenomics (MG) sequencing of 245 non-small cell lung cancer (NSCLC) patient feces, we constructed species-level co-abundance networks that were clustered into species-interacting groups (SIGs) correlating with overall survival. Thirty-seven and forty-five MG species (MGSs) were associated with resistance...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20;187(13):3373-3389.e16. doi: 10.1016/j.cell.2024.05.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gut microbiota influences the clinical responses of cancer patients to immunecheckpoint inhibitors (ICIs). However, there is no consensus definition of detrimental dysbiosis. Based on metagenomics (MG) sequencing of 245 non-small cell lung cancer (NSCLC) patient feces, we constructed species-level co-abundance networks that were clustered into species-interacting groups (SIGs) correlating with overall survival. Thirty-seven and forty-five MG species (MGSs) were associated with resistance (SIG1) and response (SIG2) to ICIs, respectively. When combined with the quantification of Akkermansia species, this procedure allowed a person-based calculation of a topological score (TOPOSCORE) that was validated in an additional 254 NSCLC patients and in 216 genitourinary cancer patients. Finally, this TOPOSCORE was translated into a 21-bacterial probe set-based qPCR scoring that was validated in a prospective cohort of NSCLC patients as well as in colorectal and melanoma patients. This approach could represent a dynamic diagnosis tool for intestinal dysbiosis to guide personalized microbiota-centered interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38906102/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38906102</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.029>10.1016/j.cell.2024.05.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38906102</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Lisa Derosa</dc:creator>
<dc:creator>Valerio Iebba</dc:creator>
<dc:creator>Carolina Alves Costa Silva</dc:creator>
<dc:creator>Gianmarco Piccinno</dc:creator>
<dc:creator>Guojun Wu</dc:creator>
<dc:creator>Leonardo Lordello</dc:creator>
<dc:creator>Bertrand Routy</dc:creator>
<dc:creator>Naisi Zhao</dc:creator>
<dc:creator>Cassandra Thelemaque</dc:creator>
<dc:creator>Roxanne Birebent</dc:creator>
<dc:creator>Federica Marmorino</dc:creator>
<dc:creator>Marine Fidelle</dc:creator>
<dc:creator>Meriem Messaoudene</dc:creator>
<dc:creator>Andrew Maltez Thomas</dc:creator>
<dc:creator>Gerard Zalcman</dc:creator>
<dc:creator>Sylvie Friard</dc:creator>
<dc:creator>Julien Mazieres</dc:creator>
<dc:creator>Clarisse Audigier-Valette</dc:creator>
<dc:creator>Denis Moro- Sibilot</dc:creator>
<dc:creator>François Goldwasser</dc:creator>
<dc:creator>Arnaud Scherpereel</dc:creator>
<dc:creator>Hervé Pegliasco</dc:creator>
<dc:creator>François Ghiringhelli</dc:creator>
<dc:creator>Nicole Bouchard</dc:creator>
<dc:creator>Cissé Sow</dc:creator>
<dc:creator>Ines Darik</dc:creator>
<dc:creator>Silvia Zoppi</dc:creator>
<dc:creator>Pierre Ly</dc:creator>
<dc:creator>Anna Reni</dc:creator>
<dc:creator>Romain Daillère</dc:creator>
<dc:creator>Eric Deutsch</dc:creator>
<dc:creator>Karla A Lee</dc:creator>
<dc:creator>Laura A Bolte</dc:creator>
<dc:creator>Johannes R Björk</dc:creator>
<dc:creator>Rinse K Weersma</dc:creator>
<dc:creator>Fabrice Barlesi</dc:creator>
<dc:creator>Lucas Padilha</dc:creator>
<dc:creator>Ana Finzel</dc:creator>
<dc:creator>Morten L Isaksen</dc:creator>
<dc:creator>Bernard Escudier</dc:creator>
<dc:creator>Laurence Albiges</dc:creator>
<dc:creator>David Planchard</dc:creator>
<dc:creator>Fabrice André</dc:creator>
<dc:creator>Chiara Cremolini</dc:creator>
<dc:creator>Stéphanie Martinez</dc:creator>
<dc:creator>Benjamin Besse</dc:creator>
<dc:creator>Liping Zhao</dc:creator>
<dc:creator>Nicola Segata</dc:creator>
<dc:creator>Jérôme Wojcik</dc:creator>
<dc:creator>Guido Kroemer</dc:creator>
<dc:creator>Laurence Zitvogel</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome</dc:title>
<dc:identifier>pmid:38906102</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.029</dc:identifier>
</item>
<item>
<title>FilamentID reveals the composition and function of metabolic enzyme polymers during gametogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38906101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Gamete formation and subsequent offspring development often involve extended phases of suspended cellular development or even dormancy. How cells adapt to recover and resume growth remains poorly understood. Here, we visualized budding yeast cells undergoing meiosis by cryo-electron tomography (cryoET) and discovered elaborate filamentous assemblies decorating the nucleus, cytoplasm, and mitochondria. To determine filament composition, we developed a "filament identification" (FilamentID)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20;187(13):3303-3318.e18. doi: 10.1016/j.cell.2024.04.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gamete formation and subsequent offspring development often involve extended phases of suspended cellular development or even dormancy. How cells adapt to recover and resume growth remains poorly understood. Here, we visualized budding yeast cells undergoing meiosis by cryo-electron tomography (cryoET) and discovered elaborate filamentous assemblies decorating the nucleus, cytoplasm, and mitochondria. To determine filament composition, we developed a "filament identification" (FilamentID) workflow that combines multiscale cryoET/cryo-electron microscopy (cryoEM) analyses of partially lysed cells or organelles. FilamentID identified the mitochondrial filaments as being composed of the conserved aldehyde dehydrogenase Ald4<sup>ALDH2</sup> and the nucleoplasmic/cytoplasmic filaments as consisting of acetyl-coenzyme A (CoA) synthetase Acs1<sup>ACSS2</sup>. Structural characterization further revealed the mechanism underlying polymerization and enabled us to genetically perturb filament formation. Acs1 polymerization facilitates the recovery of chronologically aged spores and, more generally, the cell cycle re-entry of starved cells. FilamentID is broadly applicable to characterize filaments of unknown identity in diverse cellular contexts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38906101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38906101</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.026>10.1016/j.cell.2024.04.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38906101</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jannik Hugener</dc:creator>
<dc:creator>Jingwei Xu</dc:creator>
<dc:creator>Rahel Wettstein</dc:creator>
<dc:creator>Lydia Ioannidi</dc:creator>
<dc:creator>Daniel Velikov</dc:creator>
<dc:creator>Florian Wollweber</dc:creator>
<dc:creator>Adrian Henggeler</dc:creator>
<dc:creator>Joao Matos</dc:creator>
<dc:creator>Martin Pilhofer</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>FilamentID reveals the composition and function of metabolic enzyme polymers during gametogenesis</dc:title>
<dc:identifier>pmid:38906101</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.026</dc:identifier>
</item>
<item>
<title>A brainstem maestro conducting the somatic and autonomic motor symphony</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38906100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Somatic and sympathetic tones fluctuate together seamlessly across daily behaviors. In this issue of Cell, Zhang et al. describe populations of spinal projecting neurons in the rostral ventromedial medulla (rVMM) that harmonize somatic motor function and sympathetic activation. The coordinated regulation plays a vital role in supporting behaviors associated with various arousal states.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20;187(13):3233-3235. doi: 10.1016/j.cell.2024.05.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Somatic and sympathetic tones fluctuate together seamlessly across daily behaviors. In this issue of Cell, Zhang et al. describe populations of spinal projecting neurons in the rostral ventromedial medulla (rVMM) that harmonize somatic motor function and sympathetic activation. The coordinated regulation plays a vital role in supporting behaviors associated with various arousal states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38906100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38906100</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.019>10.1016/j.cell.2024.05.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38906100</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaolin Huang</dc:creator>
<dc:creator>Yang Dan</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A brainstem maestro conducting the somatic and autonomic motor symphony</dc:title>
<dc:identifier>pmid:38906100</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.019</dc:identifier>
</item>
<item>
<title>Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38906099/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Numerous studies have evaluated the gut microbiome as a biomarker for predicting cancer immunotherapy, but the heterogeneity among different studies has hindered its applications. In this issue of Cell, Derosa et al. report a biomarker based on the ecological topology of the gut microbiota that can predict immunotherapy efficacy effectively.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20;187(13):3231-3232. doi: 10.1016/j.cell.2024.04.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Numerous studies have evaluated the gut microbiome as a biomarker for predicting cancer immunotherapy, but the heterogeneity among different studies has hindered its applications. In this issue of Cell, Derosa et al. report a biomarker based on the ecological topology of the gut microbiota that can predict immunotherapy efficacy effectively.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38906099/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38906099</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.044>10.1016/j.cell.2024.04.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38906099</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Lijun Ning</dc:creator>
<dc:creator>Jie Hong</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy</dc:title>
<dc:identifier>pmid:38906099</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.044</dc:identifier>
</item>
<item>
<title>Shinya Yamanaka</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38906098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240626081808&amp;v=2.18.0.post9+e462414
      <description>Dr. Shinya Yamanaka is recognized for his discovery of the induction of pluripotent stem cells from fibroblasts by a combination of defined factors. In this interview with Cell, he discusses the progress of the field, what's next for clinical applications of iPS cells, and the state of science in Japan and the rest of the world.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20;187(13):3229-3230. doi: 10.1016/j.cell.2024.05.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dr. Shinya Yamanaka is recognized for his discovery of the induction of pluripotent stem cells from fibroblasts by a combination of defined factors. In this interview with Cell, he discusses the progress of the field, what's next for clinical applications of iPS cells, and the state of science in Japan and the rest of the world.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38906098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240626081808&v=2.18.0.post9+e462414">38906098</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.040>10.1016/j.cell.2024.05.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38906098</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Shinya Yamanaka</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Shinya Yamanaka</dc:title>
<dc:identifier>pmid:38906098</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.040</dc:identifier>
</item>





























</channel>
</rss>